CN113876777A - 尼达尼布治疗异常新生血管形成骨关节疾病的方法 - Google Patents
尼达尼布治疗异常新生血管形成骨关节疾病的方法 Download PDFInfo
- Publication number
- CN113876777A CN113876777A CN202111225652.1A CN202111225652A CN113876777A CN 113876777 A CN113876777 A CN 113876777A CN 202111225652 A CN202111225652 A CN 202111225652A CN 113876777 A CN113876777 A CN 113876777A
- Authority
- CN
- China
- Prior art keywords
- nintedanib
- diseases
- abnormal neovascularization
- osteoarticular
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 title claims abstract description 31
- 229960004378 nintedanib Drugs 0.000 title claims abstract description 31
- 206010029113 Neovascularisation Diseases 0.000 title claims abstract description 26
- 230000002159 abnormal effect Effects 0.000 title claims abstract description 25
- 201000010099 disease Diseases 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 18
- 208000012659 Joint disease Diseases 0.000 claims abstract description 12
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 9
- 239000002674 ointment Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 5
- 239000000725 suspension Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims abstract description 4
- 206010006811 Bursitis Diseases 0.000 claims abstract description 3
- 206010034464 Periarthritis Diseases 0.000 claims abstract description 3
- 208000036319 cervical spondylosis Diseases 0.000 claims abstract description 3
- 239000006071 cream Substances 0.000 claims abstract description 3
- 208000005801 spondylosis Diseases 0.000 claims abstract description 3
- 239000007939 sustained release tablet Substances 0.000 claims abstract description 3
- 201000004595 synovitis Diseases 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000002188 osteogenic effect Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 206010005963 Bone formation increased Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 206010048873 Traumatic arthritis Diseases 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了尼达尼布治疗异常新生血管形成骨关节疾病的方法，其包括尼达尼布通过添加辅料制备成药剂，以全身或局部的给药至骨关节疾病处，能够加快骨关节疾病恢复正常。所述异常新生血管形成的骨关节疾病包括退行性关节炎、滑囊炎、滑膜炎、颈椎病。所述异常新生血管形成的骨关节疾病包括腰椎病、肩周炎等，所述外用制剂为溶液、悬浮液、乳膏、软膏剂、凝胶、凝胶形成性液体等与口服制剂的其中一种，所述口服制剂包括片剂、缓释片或液体。本发明将尼达尼布用于临床治疗异常新生血管形成的骨关节疾病将会帮助这类患者尽快恢复，本发明将尼达尼布发掘了新的医疗用途开拓了一个新的应用领域，对异常新生血管形成的骨关节疾病治疗产生重大意义。
Description
技术领域
本发明涉及医药技术领域，具体是指尼达尼布治疗异常新生血管形成骨关节疾病的方法。
背景技术
尼达尼布是一种新型的血管生成抑制剂，可同时作用于血管生成过程中涉及的3种关键受体家族：血管内皮生长因子受体(VEGFR)、血小板源性生长因子受体(PDGFR)以及成纤维细胞生长因子受体(FGFR)。尼达尼布已被FDA和EMA批准上市，用于治疗特发性肺纤维化(IPF)，也被EMA批准联合多西他赛在一线化疗之后应用于组织学诊断为腺癌的、局部晚期或转移性或局部复发性非小细胞肺癌(NSCLC)成年患者。目前，现有的很多骨关节疾病与异常新生血管有关，但是没有有效的方法来治疗异常新生血管形成骨关节疾病。
发明内容
鉴于此，本发明的目的在于提供尼达尼布治疗异常新生血管形成骨关节疾病的方法以解决现有技术存在的问题。
尼达尼布治疗异常新生血管形成骨关节疾病的方法，其特征在于，其包括尼达尼布通过添加辅料制备成药剂，以全身或局部的给药至骨关节疾病处，能够加快骨关节疾病恢复正常。
进一步的，所述异常新生血管形成的骨关节疾病包括退行性关节炎、滑囊炎、滑膜炎、颈椎病。
进一步的，所述异常新生血管形成的骨关节疾病包括腰椎病、肩周炎、骨质增生、风湿性关节炎、类风湿性关节炎、股骨头坏死、膝关节炎。
进一步的，所述外用制剂为溶液、悬浮液、乳膏、软膏剂、凝胶、凝胶形成性液体等与口服制剂的其中一种。
进一步的，所述给药可通过注射、外用或口服。
进一步的，所述药剂是含有脂质体或胶束的悬浮液、喷雾配制剂或乳剂中的其中一种以及与口服制剂的其中一种，所述口服制剂包括片剂、缓释片或液体。
进一步的，所述异常新生血管形成的骨关节疾病包括原发性骨关节病和继发性骨关节病。
进一步的，所述异常新生血管形成的骨关节疾病包括骨性关节炎，创伤性关节炎，痛风性关节炎、血友病型关节炎。
采用上述技术方案，具有如下有益效果：
本发明将尼达尼布用于临床治疗异常新生血管形成的骨关节疾病将会帮助这类患者尽快恢复，本发明将尼达尼布发掘了新的医疗用途开拓了一个新的应用领域，对异常新生血管形成的骨关节疾病治疗产生重大意义。
具体实施方式
下面对本发明的技术方案更为详细、完整的说明。
实施例1：本发明的目的在于提供一种尼达尼布的新用途，本实施例通过尼达尼布针对异常新生血管形成的骨关节疾病的临床应用及结果分析：
临床显示：将尼达尼布添加辅料制成外用软膏剂，软膏剂中，尼达尼布的含量为10％，在进行使用钱，涂抹在人体皮肤上无明显急性毒性反应、无刺激性、不产生局部及全身过敏反应。
实施例2：本实施例通过尼达尼布针对异常新生血管形成的骨关节疾病的临床应用及结果分析：
临床显示：将尼达尼布添加辅料制成外用软膏剂，软膏剂中，尼达尼布的含量为40％，在进行使用钱，涂抹在人体皮肤上无明显急性毒性反应、无刺激性、不产生局部及全身过敏反应。
实施例3：本实施例通过尼达尼布针对异常新生血管形成的骨关节疾病的临床应用及结果分析：
临床显示：将尼达尼布添加辅料制成外用软膏剂，软膏剂中，尼达尼布的含量为80％，在进行使用钱，涂抹在人体皮肤上无明显急性毒性反应、无刺激性、不产生局部及全身过敏反应。
本发明中实施例1-实施例3中的试验对象均为患有异常新生血管形成骨关节疾病的患者，患者的患病年龄在20-70岁，患病时长最短1年，最长10年。
| 治疗天数 | 实施例1(治疗率％) | 实施例2(治疗率％) | 实施例3(治疗率％) |
| 30天 | 20 | 40 | 50 |
| 60天 | 40 | 60 | 80 |
| 90天 | 60 | 70 | 90 |
根据上述结果表明：将尼达尼布对治疗新生血管形成的皮肤疾病有很好的治疗效果。
因此，尼达尼布治疗异常新生血管形成的骨关节疾病的方法，其包括尼达尼布通过添加辅料制备成药剂以局部的给药能够加快皮肤疾病愈合并恢复正常。
以上描述了本发明的基本原理和主要特征，本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内，发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (8)
1.尼达尼布治疗异常新生血管形成骨关节疾病的方法，其特征在于，其包括尼达尼布通过添加辅料制备成药剂，以全身或局部的给药至骨关节疾病处，能够加快骨关节疾病恢复正常。
2.根据权利要求1所述的尼达尼布治疗异常新生血管形成骨关节疾病的方法，其特征在于，所述异常新生血管形成的骨关节疾病包括退行性关节炎、滑囊炎、滑膜炎、颈椎病。
3.根据权利要求1所述的尼达尼布治疗异常新生血管形成骨关节疾病的方法，其特征在于，所述异常新生血管形成的骨关节疾病包括腰椎病、肩周炎、骨质增生、风湿性关节炎、类风湿性关节炎、股骨头坏死、膝关节炎。
4.根据权利要求1所述的尼达尼布治疗异常新生血管形成骨关节疾病的方法，其特征在于，所述外用制剂为溶液、悬浮液、乳膏、软膏剂、凝胶、凝胶形成性液体等与口服制剂的其中一种。
5.根据权利要求1所述的尼达尼布治疗异常新生血管形成骨关节疾病的方法，其特征在于，所述给药可通过注射、外用或口服。
6.根据权利要求1所述的尼达尼布治疗异常新生血管形成骨关节疾病的方法，其特征在于，所述药剂是含有脂质体或胶束的悬浮液、喷雾配制剂或乳剂中的其中一种以及与口服制剂的其中一种，所述口服制剂包括片剂、缓释片或液体。
7.根据权利要求1所述的尼达尼布治疗异常新生血管形成骨关节疾病的方法，其特征在于，所述异常新生血管形成的骨关节疾病包括原发性骨关节病和继发性骨关节病。
8.根据权利要求1所述的尼达尼布治疗异常新生血管形成骨关节疾病的方法，其特征在于，所述异常新生血管形成的骨关节疾病包括骨性关节炎，创伤性关节炎，痛风性关节炎、血友病型关节炎。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111225652.1A CN113876777A (zh) | 2021-10-21 | 2021-10-21 | 尼达尼布治疗异常新生血管形成骨关节疾病的方法 |
| PCT/CN2022/125885 WO2023066241A1 (zh) | 2021-10-21 | 2022-10-18 | 尼达尼布治疗异常新生血管形成骨关节疾病的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111225652.1A CN113876777A (zh) | 2021-10-21 | 2021-10-21 | 尼达尼布治疗异常新生血管形成骨关节疾病的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113876777A true CN113876777A (zh) | 2022-01-04 |
Family
ID=79004000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111225652.1A Withdrawn CN113876777A (zh) | 2021-10-21 | 2021-10-21 | 尼达尼布治疗异常新生血管形成骨关节疾病的方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113876777A (zh) |
| WO (1) | WO2023066241A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023066241A1 (zh) * | 2021-10-21 | 2023-04-27 | 张国华 | 尼达尼布治疗异常新生血管形成骨关节疾病的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017207643A1 (en) * | 2016-06-01 | 2017-12-07 | Boehringer Ingelheim International Gmbh | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
| US20190388407A1 (en) * | 2017-02-12 | 2019-12-26 | Aiviva Biopharma, Inc. | Multikinase inhibitors of vegf and tfg beta and uses thereof |
| CN113876777A (zh) * | 2021-10-21 | 2022-01-04 | 张国华 | 尼达尼布治疗异常新生血管形成骨关节疾病的方法 |
-
2021
- 2021-10-21 CN CN202111225652.1A patent/CN113876777A/zh not_active Withdrawn
-
2022
- 2022-10-18 WO PCT/CN2022/125885 patent/WO2023066241A1/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023066241A1 (zh) * | 2021-10-21 | 2023-04-27 | 张国华 | 尼达尼布治疗异常新生血管形成骨关节疾病的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023066241A1 (zh) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Westerman et al. | Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study | |
| WO2016062283A1 (zh) | 抗发炎用药物在制备抑制癌症的医药组合物中的应用 | |
| JP2020158521A (ja) | Ｅｆｐの治療または低減方法 | |
| AU2002224475B2 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
| Hazarika | Generalized pustular psoriasis of pregnancy successfully treated with cyclosporine | |
| Lin et al. | Efficacy and safety of indigo naturalis ointment in treating atopic dermatitis: a randomized clinical trial | |
| EP1476195B1 (en) | Enhancement of the action of central and peripheral nervous system agents | |
| CN113876777A (zh) | 尼达尼布治疗异常新生血管形成骨关节疾病的方法 | |
| US20140303146A1 (en) | Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias | |
| Pickering et al. | A new transmucous-buccal formulation of acetaminophen for acute traumatic pain: A non-inferiority, randomized, double-blind, clinical trial | |
| RU2535019C1 (ru) | Седативное и спазмолитическое средство | |
| US11826323B2 (en) | Method of treating a person afflicted with COVID-19 and pharmaceutical formulation including dapsone | |
| CN100354000C (zh) | α－1抗胰蛋白酶在制备用于治疗纤维肌痛的药物中的应用 | |
| CN104869994B (zh) | 匹多莫德治疗银屑病的用途 | |
| US20240058316A1 (en) | Prodrug of a phenolic trpv1 agonist for the treatment of pain | |
| US20220323481A1 (en) | Pharmaceutical composition for treatment and prevention of chronic disease | |
| CN104856948B (zh) | 一种氯雷他定糖浆剂及其制备方法 | |
| Hoskin et al. | Controlled‐release morphine in cancer pain: Is a loading dose required when the formulation is changed? | |
| Yakushin et al. | Comparison of the efficacy and safety of ketoprofen plaster and diclofenac plaster for osteoarthritis-related knee pain: A multicenter, randomized, active-controlled, open-label, parallel-group, phase III clinical trial | |
| CN114392261A (zh) | 尼达尼布治疗新生血管形成的皮肤疾病组合物和方法 | |
| Awad et al. | Liquid dosage forms | |
| TW442281B (en) | Pharmaceutical compositions for treating psoriasis and other hyperkeratotic and/or scaly dermatoses | |
| McFadden et al. | Medication delivery in the short‐bowel syndrome | |
| US20190343161A1 (en) | Therapeutic agent for chronic fatigue syndrome | |
| US20120316217A1 (en) | combination for the treatment of osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220104 |